Telomir-1 improved survival in progeria cells and normalized ROS levels under oxidative stress. The candidate reduced mitochondrial calcium overload, restoring cell energy balance. From tariffs to ...

As with other conditions, Telomir-1 treats the underlying causes of progeria by regulating metal ions, reducing oxidative stress, restore mitochondrial function, extending telomere length ...

The only FDA-approved therapy for progeria, Zokinvy® (lonafarnib), is a farnesyltransferase inhibitor that has been shown to extend lifespan by an average of 4.3 years. However, Zokinvy does not ...

The only FDA-approved therapy for progeria, Zokinvy® (lonafarnib), is a farnesyltransferase inhibitor that has been shown to extend lifespan by an average of 4.3 years.

Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1's effects on key drivers of accelerated aging MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir ...

MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company focused on reversing biological aging and age-related diseases ...